Vifor Pharma is an originally Swiss company forming the “pharma division” of the Galenica Group, which is active in the pharmaceutical and healthcare sectors. For two years Vifor Pharma had offices in the Netherlands (Utrecht) as well as Belgium (Antwerp) and has now decided to merge these into one Benelux office in Breda. On the short term 25 employees will start their activities for Vifor Pharma from the new office. It mainly concerns jobs in marketing and sales.
After having explored the region for the first time, Mr Geert ter Schure, managing director of
“In spite of, or maybe even thanks to the worldwide economic recession companies keep discovering the advantages of going Benelux”, adds Mr Cees Meeuwis, alderman for Economic Affairs of the City of Breda. “The fact that
In fact, Vifor Pharma chose
BACKGROUND INFORMATION TO VIFOR PHARMA
Vifor Pharma is the pharma division of the Swiss Galenica Group. Galenica (or „galenics“ is the science active in the method of making medicines) is a diversified group operating within the full spectrum of the healthcare market. Among other things, it develops, manufactures and sells pharmaceutical products, runs pharmacies, offers logistical and database services and sets up networks. The Galenica Group is divided into two divisions, Pharma and Health, and the four business units of Pharma, Logistics, Retail and Healthcare Information.
The Vifor Pharma flag unites all the Galenica companies involved in pharmaceutical research and development and in manufacturing and selling pharmaceutical products.
Galenica has approximately 5,500 employees worldwide and in 2009 netted a profit of S.fr. 210m (roughly € 148m)
Vifor Pharma is a specialised pharmaceutical company, based on two main business units: Rx (prescribed medicine) and Consumer Healthcare (OTC = over the counter, so freely available products). The company’s special aims are research, development, production and marketing of both its own and license-manufactured products against anaemia, kidney diseases and diseases of the auto-immune system.
Furthermore, Vifor Pharma offers a wide range of self-produced, acquired or licence-produced OTC products that are marketed by its own organisation in the larger European countries. Vifor Pharma is growing, as is its global presence. All its products are centrally produced in
To realise its business targets, Vifor Pharma regularly closes strategic alliances and joint ventures. For example, Vifor announced on 2nd December last that it will intensify its present cooperation with Fresenius Medical Care (FMC) by jointly setting up a specialised pharmaceutical company in the field of nephrology, the science of kidney diseases. The new organisation will supply innovative and very advanced products to improve the quality of life of people suffering from Chronic Kidney Disease (CKD) worldwide. Among other things, this is done with products called Venofer® and Ferinject® which are used in dialysis and pre-dialysis (CKD stage III – V) and PA21, a pioneering iron-based phosphate binder.
Posted on 18-01-2011